In contrast, CSF tau and P-tau did not predict development of AD/DLB over 9 years and the ratios of CSF Aβ42/tau or Aβ42/P-tau did not improve the predictive ability compared with CSF Aβ42 alone. This evidence concerns the gene MAPT and Alzheimer disease.